Nurix lands $700M upfront in Roche deal for BTK degrader, up to $2.3B total at stake

Filed June 8, 2026 · Period ending June 6, 2026 · ~1 min read

Key Changes

• high

  Roche pays $700 million cash upfront to license bexobrutideg, Nurix's experimental brain-penetrant BTK degrader, with up to $1.6 billion more in milestone payments tied to development, regulatory approval, and sales performance.

  Item 1.01: Material Agreement verify on EDGAR →
• high

  Nurix must fund 40% of global development costs and build a U.S. sales force, raising concerns about whether the company has adequate resources—potentially requiring future capital raises despite the large upfront payment.

  Item 1A: Risk Factors view on EDGAR →
• high

  Companies will split U.S. profits equally; Nurix receives low-to-high teens royalties on ex-U.S. sales, retaining significant economics but also bearing substantial cost obligations across multiple clinical trials.

  Item 1.01: Cost Sharing verify on EDGAR →